Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Somewhat Bullish +50

Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy?

📉 Moderna has the highest short interest of any S&P 500 stock, with hedge funds selling 17.8% of its float short.

💰 U.S. revenue declined to $1.2 billion last year and CFO Jamey Mock warned of another decline to roughly $1 billion in 2026.

🌍 International revenue is expected to reach $1 billion in 2026 due to multi-year contracts with the UK, Canada, and Australia.

💉 Moderna's personalized cancer vaccine 'intismeran' could read out Phase III trial results in 2026 with potential blockbuster commercial value.

🏥 The company has eight late-stage cancer studies running across multiple tumor types including melanoma, lung, bladder, and renal cell carcinoma.

💧 A Phase III readout for a norovirus vaccine is also expected in 2026, while the standalone flu vaccine targets a U.S. approval date of Aug. 5.

💸 Moderna expects $1.9 billion revenue at the high end of guidance for 2025 and aims to achieve over $1 billion in cost reductions.

💵 The company maintains a strong cash balance of $8.1 billion as it executes its strategy.

🇪🇺 A competitor's contract locking Moderna out of Europe's respiratory vaccine market expires later this year, opening a $1.8 billion opportunity.

⚠️ Analyst price targets average $43.80, which is below the current stock price of approximately $50.

📊 Out of 24 analysts covering MRNA, nine recommend "Strong Buy" or "Hold," while six recommend "Sell."

Bullish Signals
  • Moderna has locked in multi-year strategic partnerships with the United Kingdom, Canada, and Australia, providing revenue visibility that most biotech companies don't have.
  • The company generated $700 million in international revenue in 2025 and expects that number to climb to $1 billion in 2026.
  • Moderna's personalized cancer vaccine intismeran has shown remarkable Phase II data with a three-year hazard ratio of 0.51 on recurrence-free survival, and a Phase III readout could occur as early as 2026.
  • The company has eight late-stage cancer studies running across various indications including melanoma, renal cell carcinoma, bladder cancer, and lung cancer.
  • Moderna's standalone flu vaccine received a positive CHMP opinion in Europe, meaning it could arrive ready to compete when the respiratory vaccine market opens up in 2027.
  • Management guided for up to 10% total revenue growth in 2026, with international revenues being the primary driver of this expansion.
  • Moderna has projected $1.9 billion in revenue for 2025 at the high end of guidance and plans cost reductions exceeding targets while maintaining a cash balance of $8.1 billion.
Risk Factors
  • Moderna's U.S. revenue fell to $1.2 billion last year and the CFO acknowledged another decline is planned for 2026, dropping to roughly $1 billion.
  • The company plans a 20% year-over-year revenue decrease in the U.S. market specifically, which could weigh on overall growth despite international expectations.
  • Hedge funds hold a short interest of 17.8%, representing the highest short interest of any S&P 500 stock, indicating significant Wall Street skepticism.
  • Moderna continues to burn cash on a sprawling pipeline of drugs that have not yet hit the market.
  • The average analyst price target is $43.80, which is below the current stock price of about $50.
  • Analyst sentiment is mixed with only two 'Strong Buy' recommendations out of 24 analysts covering the stock, while one firm recommends a 'Strong Sell'.
  • Moderna's standalone flu vaccine has a U.S. PDUFA date of Aug. 5, but approval is not guaranteed and represents a delayed revenue stream until 2027.
Full Analysis
Moderna (MRNA) currently holds the highest short interest of any S&P 500 stock, with hedge funds selling short 17.8% of its float according to Bank of America's equity team. This high short position reflects significant bearish sentiment driven by concerns over declining COVID-19 vaccination rates and waning U.S. revenue, which fell to $1.2 billion last year. C-suite executives at the TD Cowen 46th Annual Health Care Conference in March confirmed that U.S. revenue is expected to drop further to approximately $1 billion in 2026, a 20% year-over-year decline from previous levels, as Chief Financial Officer Jamey Mock noted during his presentation on the company's financial outlook. However, analysts point out that short sellers may be undervaluing Moderna's diversification strategy beyond its domestic vaccine portfolio. Despite U.S. revenue headwinds, the company guided for up to 10% total revenue growth in 2026, primarily driven by international markets where it has secured multi-year contracts with governments in the United Kingdom, Canada, and Australia. International revenue is projected to reach $700 million in 2025 and $1 billion in 2026, providing a stable revenue floor that contrasts sharply with domestic trends. Additionally, Europe is anticipated to open up for respiratory vaccines in 2027 after a competitor's contract expires later this year, coinciding with Moderna's positive Committee for Medicinal Products for Human Use opinion on its flu/Covid combination vaccine. The company's future growth potential hinges heavily on its pipeline, particularly the personalized cancer vaccine intismeran developed in partnership with Merck (MRK). The Phase III trial for adimmerin melanoma could read out in 2026, following remarkable Phase II data that showed a hazard ratio of 0.51 on recurrence-free survival at the three-year mark. Moderna also has eight late-stage cancer studies across multiple cancer types, including renal cell carcinoma and lung cancer, alongside a norovirus vaccine with a Phase III readout expected in 2026 and its standalone flu vaccine targeting PDUFA approval by August 5. Management expects strong execution in 2025, with revenue potentially reaching $1.9 billion at the high end of guidance, cost reductions exceeding targets, and a cash balance of $8.1 billion. Current market consensus remains cautious, with only two of 24 analysts recommending "Strong Buy," while most favor a "Hold" rating; however, the average stock price target stands at $43.80, which is below the current trading price of approximately $50. This discrepancy suggests that contrarian investors see value in the company's diversified revenue streams and late-stage pipeline catalysts that may not be fully reflected in the current short interest. While the U.S. market faces near-term headwinds with anticipated revenue declines through 2026, the broader international portfolio and oncology potential present a different narrative for long-term investors watching for a revaluation of the stock based on non-COVID revenue generation.